Go to podcast
by The Lancet Respiratory Medicine
In conversation with...

Treatment options in patients with systemic sclerosis-associated interstitial lung disease

Description

Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.

Details

Episode

by The Lancet Respiratory Medicine